This is good news for patients. I expect down the road, once approved, B-OM will be used in combo with one or more other OM treatments. The topical application and low systemic absorption means it should pair well with other treatments.
I wouldn't be surprised to see these two paired together in a trial measuring incidence of mild OM. Hopefully severe OM will be a thing of the past once we perfect our delivery system and we'll keep pushing that state of care higher and higher.
Go IPIX!
(2)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.